Vertex to highlight anti-HCV activity of VX-950 at annual meeting in Vienna

By Lisa Kerner

Erie, Pa., April 26 - Vertex Pharmaceuticals Inc. will present new data supporting clinical development of VX-950, an investigational oral hepatitis C virus (HCV) protease inhibitor for the treatment of hepatitis C, at the 41st Annual Meeting of the European Association for the Study of the Liver in Vienna.

The first presentation describes long-term viral sequencing follow-up data of patients previously dosed with VX-950 as a single agent for 14 days.

In a second presentation, researchers will describe results of a whole genome analysis suggesting that the expression level of interferon-sensitive genes may be restored with VX-950 treatment.

"Data from early clinical studies have consistently shown a rapid and dramatic reduction in viral load in patients treated with VX-950, with good tolerability," chief medical officer John Alam said in a company news release.

"We are pleased to share the results of these extensive viral sequencing and gene expression analyses with the HCV medical community and discuss the implications of our findings for future clinical studies."

Vertex is a Cambridge, Mass.-based biotechnology company specializing in small molecule drugs.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.